Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study
Authors' conclusion
Later-stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.
Study context
- Population
- Adults with BMI ≥30 kg/m² with an initial antiobesity medication (AOM) prescription filled 2015–2022; EHR of a large health system in Ohio and Florida
- Participants
- 1,911 adults
- Exposure
- AOM categories for 1-year persistence
- Outcome
- Persistence with AOM
- Follow-up
- 3, 6 and 12 months
Main finding
As reported in the abstract
Persistent at 3 months
44%
Persistent at 6 months
33%
Persistent at 12 months
19%
Observational data: associations, not effects.
Further findings
| Outcome | Semaglutide | aOR (95% CI) | |
|---|---|---|---|
| 1-year persistence by AOMSemaglutidevs Phentermine-topiramateHigher odds | 40% | 4.26 (3.04–6.05) | |
| 1-year persistence by AOMNaltrexone-bupropionvs Phentermine-topiramateLower odds | 0.68 (0.46–1.00) | ||
| 0.10.31310Adjusted odds ratio (log scale) |
- 1-year persistence by AOM: highest 1-year persistence with semaglutide
Persistence at year 1 per 1% increase in weight loss at 6 months (patients persistent at 6 months)
- aOR per 1% increase in weight loss
- 1.06 (95% CI: 1.03-1.09)
Original publication
Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study. Obesity (Silver Spring). Published 6 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →